Veracyte to Present at the UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 9, 2019--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the UBS Global Healthcare Conference in New York City on Monday, May 20, 2019 at 9:30 a.m. EDT.
The link to the live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions. The company’s products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. Since its founding in 2008, Veracyte has commercialized five genomic tests which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
View source version on businesswire.com:https://www.businesswire.com/news/home/20190509005849/en/
CONTACT: Veracyte Investor & Media Contact:
Vice President, Investor Relations & Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL
SOURCE: Veracyte, Inc.
Copyright Business Wire 2019.
PUB: 05/09/2019 04:20 PM/DISC: 05/09/2019 04:20 PM